Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-H9 weekly or biweekly vs daily Genotropin in paediatric growth hormone deficiency (phase 2 dose-finding)
2015-001939-21Phase 2Completed
- Sponsor
- Genexine
- Start
- May 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eftansomatropin alfa in growth hormone deficiency (GHD) (4 arms), sponsored by Genexine. Primary endpoint: Efficacy endpoints. Started May 2015; status: completed.
02
Drugs
eftansomatropin alfa
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2015-001939-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001939-21.